Legal & General Group Plc Makes New Investment in OPKO Health, Inc. $OPK

Legal & General Group Plc bought a new position in OPKO Health, Inc. (NASDAQ:OPK) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 346,787 shares of the biotechnology company’s stock, valued at approximately $520,000.

Several other institutional investors also recently modified their holdings of OPK. Zacks Investment Management purchased a new stake in shares of OPKO Health during the fourth quarter valued at approximately $27,000. StoneX Group Inc. bought a new stake in OPKO Health during the fourth quarter worth $27,000. Apella Capital LLC purchased a new position in OPKO Health in the first quarter worth $34,000. Cibc World Markets Corp purchased a new position in OPKO Health in the fourth quarter worth $34,000. Finally, Diversify Advisory Services LLC bought a new position in OPKO Health in the 2nd quarter valued at $37,000. 64.63% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on OPK shares. HC Wainwright reaffirmed a “buy” rating on shares of OPKO Health in a research report on Wednesday, July 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, August 13th. Finally, Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, OPKO Health has an average rating of “Hold” and an average price target of $1.55.

OPKO Health Price Performance

Shares of NASDAQ:OPK opened at $1.59 on Wednesday. The firm has a market capitalization of $1.19 billion, a PE ratio of -17.67 and a beta of 1.50. The company has a quick ratio of 2.93, a current ratio of 3.35 and a debt-to-equity ratio of 0.28. The company has a 50-day moving average price of $1.40 and a two-hundred day moving average price of $1.30. OPKO Health, Inc. has a twelve month low of $0.98 and a twelve month high of $1.73.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.07. The company had revenue of $163.58 million for the quarter, compared to analyst estimates of $131.23 million. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.19) earnings per share. Equities analysts forecast that OPKO Health, Inc. will post -0.23 EPS for the current year.

OPKO Health Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.